Upper tract urothelial carcinoma (UTUC), which harbors mutations in FGFR3 in 74% of patients44, exhibited a particularly poor response to adjuvant nivolumab in the CheckMate274 trial45 (HR = 1.16, 95% CI = 0.62–2.13 for renal pelvis, and 1.55 (0.7–3.45) for ureteral tumors). Here, FGFR3 is linked to ureter neoplasm.